作者
John Gregson, Michele Tang, Nicaise Ndembi, Raph L Hamers, Soo-Yon Rhee, Vincent C Marconi, Lameck Diero, Katherine A Brooks, Kristof Theys, Tobias Rinke de Wit, Monica Arruda, Frederico Garcia, Susana Monge, Huldrych F Günthard, Christopher J Hoffmann, Phyllis J Kanki, Nagalingeshwaran Kumarasamy, Bernard Kerschberger, Orna Mor, Charlotte Charpentier, Eva Todesco, Casper Rokx, Luuk Gras, Elias K Helvas, Henry Sunpath, Domenico Di Carlo, Antonio Antinori, Massimo Andreoni, Alessandra Latini, Cristina Mussini, Avelin Aghokeng, Anders Sonnerborg, Ujjwal Neogi, William J Fessel, Simon Agolory, Chunfu Yang, Jose L Blanco, James M Juma, Erasmus Smit, Daniel Schmidt, Christine Watera, Juliet Asio, Wilford Kurungi, Anna Tostevin, Tal El-Hay, Nathan Clumeck, Dominique Goedhals, Cloete Van Vuuren, Philip A Bester, Caroline Sabin, Irene Mukui, Maria M Santoro, Carlo F Perno, Gillian Hunt, Lynn Morris, Ricardo Camacho, Tulio De Oliveira, Deenan Pillay, Eugene Schulter, Akio Murakami-Ogasawara, Gustavo Reyes-Teran, Karla Romero, Santiago Avila-Rios, Sunee Sirivichayakul, Kiat Ruxrungtham, Suwanna Mekprasan, David Dunn, Pontiano Kaleebu, Elliot Raizes, Rami Kantor, Robert W Shafer, Ravindra K Gupta
发表日期
2016/5/1
期刊
The Lancet infectious diseases
卷号
16
期号
5
页码范围
565-575
出版商
Elsevier
简介
Background
Antiretroviral therapy (ART) is crucial for controlling HIV-1 infection through wide-scale treatment as prevention and pre-exposure prophylaxis (PrEP). Potent tenofovir disoproxil fumarate-containing regimens are increasingly used to treat and prevent HIV, although few data exist for frequency and risk factors of acquired drug resistance in regions hardest hit by the HIV pandemic. We aimed to do a global assessment of drug resistance after virological failure with first-line tenofovir-containing ART.
Methods
The TenoRes collaboration comprises adult HIV treatment cohorts and clinical trials of HIV drug resistance testing in Europe, Latin and North America, sub-Saharan Africa, and Asia. We extracted and harmonised data for patients undergoing genotypic resistance testing after virological failure with a first-line regimen containing tenofovir plus a cytosine analogue (lamivudine or emtricitabine) plus a non …
学术搜索中的文章
J Gregson, M Tang, N Ndembi, RL Hamers, SY Rhee… - The Lancet infectious diseases, 2016
